To cite this paper use one of the standards below:
Enzyme replacement therapy using recombinant enzyme was the first therapeutic option for Gaucher disease approved by FDA.1 This study evaluated how the histone deacetylase inhibitor SAHA interferes in the β-glycosylceramidase (GBA) production. First, the dose of SAHA inhibitor was established. Then the cell lines were treated with SAHA for 48 hour and the GBA enzymatic activity was measured by the fluorimetric enzyme assy.2 Following the treatment, the transgenic cell line showed a 2.04-fold increase in intracellular GBA (p<0.0001) and a 1.9-fold inhibition of secreted GBA (p<0,0001). For the virgin cell line, we observed an increase in intracellular enzyme about 3.8-fold (p=0.0001) and an increase in the level of secreted GBA enzyme, approximately 2.06-fold (p=0.006). Spearman correlation showed a significant positive correlation between the levels of secreted and intracellular GBA (rho=0.709 and p=0.027). These data show that SAHA treatment significantly increased the GBA production in both cell lines.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper